home / stock / oric / oric message board
Subject | By | Source | When |
---|---|---|---|
Price gaining last up | makinezmoney | investorshub | 06/20/2023 8:48:31 AM |
Price now | makinezmoney | investorshub | 05/30/2023 4:54:44 AM |
Price gaining | TheFinalCD | investorshub | 05/30/2023 12:36:19 AM |
$ORIC LOOKS LIKE $6 COMING | TheFinalCD | investorshub | 12/23/2022 7:14:12 PM |
$ORIC: Tapped $5.40....... still got steam | makinezmoney | investorshub | 12/23/2022 2:49:12 PM |
Today is green fields | DH112 | investorshub | 12/23/2022 12:04:52 PM |
znewcar1: $ORIC 59% v29,3M C4.79 f39,6M H5.25 ML2.91 | znewcar1 | investorshangout | 12/22/2022 9:12:27 PM |
Pfizer will pay $4.65 per share for 5,376,344 | TheFinalCD | investorshub | 12/22/2022 3:30:27 PM |
$ORIC: 5.25 now........................... lets get to $10 | makinezmoney | investorshub | 12/22/2022 3:15:11 PM |
$ORIC : Now at 4.90 | makinezmoney | investorshub | 12/22/2022 3:08:44 PM |
Shares of Oric Pharmaceuticals Inc. jumped nearly 60% | crudeoil24 | investorshub | 12/22/2022 1:09:16 PM |
$ORIC: BOOOoommmmmmm........... Pfiizer invests $25Milly in $ORIC | makinezmoney | investorshub | 12/22/2022 1:02:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Oric Pharmaceuticals Inc. Company Name:
ORIC Stock Symbol:
NASDAQ Market:
2024-06-13 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 04:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best...